Catalent gains global rights to evaluate certepetide and its analogs for use as SMARTag® payloads across multiple ADCs designed to address difficult-to-treat diseases Catalent’s preclinical study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback